Adalimumab Injection, Solution
Product Images NDC 61314-327

Product Visual Gallery

This gallery contains 36 technical images submitted to the FDA as part of the official labeling for Adalimumab (NDC 61314-327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 10b (Figure 10b)

An illustration depicting four items in sequence: a wipe packet labeled "WIPE," a cotton ball or pad, a sharps disposal container labeled "SHARPS," and a bandage or adhesive strip. The items are arranged with plus signs between them, suggesting a sequence related to injection site preparation and post-injection care.*

FDA Label Image

Fig 1 (Gp2017 Fig1)

A line graph depicting the percentage of ACR20 responders over 48 weeks. The x-axis represents time in weeks, and the y-axis represents the percent of responders. One line represents patients receiving 40 mg every other week, showing a higher response rate compared to a placebo group represented by a different line.*

FDA Label Image

Fig 2 (Gp2017 Fig2)

A line graph showing the percentage of ASAS 20 response over 26 weeks comparing Adalimumab (N=208) and Placebo (N=107). The Adalimumab group shows a higher response percentage, peaking around 8 to 10 weeks and maintaining a level above 50%, while the Placebo group peaks below 30% and decreases over time.*

FDA Label Image

Figb (Gp2017 Figc)

An instructional illustration showing items related to subcutaneous injection preparation and aftercare. From left to right, it depicts a wipe, a cotton ball or gauze pad, a sharps disposal container, and an adhesive bandage.*

FDA Label Image

Fig E (Gp2017 Fige)

Illustration showing common subcutaneous injection sites on a human body, highlighting the lower abdomen and the front upper thighs as potential areas for injection administration.*

FDA Label Image

Figee (Gp2017 Figf)

An instructional illustration showing a hand pinching and preparing the skin on a thigh for subcutaneous injection. The image features arrows indicating a slight back-and-forth motion on the skin surface, demonstrating the recommended technique before administering the injection.*

FDA Label Image

Figff (Gp2017 Figg)

An instructional illustration showing hands removing the cap from a prefilled syringe, likely for subcutaneous injection of Adalimumab solution. The image demonstrates the correct technique to uncouple the cap by pulling it away from the syringe body in preparation for injection.*

FDA Label Image

Figgg1 (Gp2017 Figh)

An instructional line drawing showing a hand holding a prefilled syringe vertically with the needle facing downwards, positioned above a surface. The image likely illustrates the proper grip or injection preparation technique for the Adalimumab injection solution.*

FDA Label Image

Figgg (Gp2017 Figh1)

Illustration showing the correct and incorrect orientation for using a prefilled injection pen. The correct position is shown vertically upright with a check mark, while the incorrect position is tilted with a cross mark. The image is related to proper usage instructions for subcutaneous injection devices.*

FDA Label Image

Fighh (Gp2017 Figi)

Illustration showing a hand holding a prefilled syringe vertically with the needle downward, positioned for subcutaneous injection. An arrow indicates downward pressure on the syringe to administer the injection, consistent with the use of Adalimumab injection, solution, subcutaneous route.*

FDA Label Image

Figii (Gp2017 Figj)

An instructional illustration showing a hand holding a syringe injection pen. The syringe is positioned vertically with a green dashed circle emphasizing the area near the needle, indicating an instructional focus on injection technique or preparation.*

FDA Label Image

Figjj (Gp2017 Figk)

An illustration showing a hand holding a pre-filled injection pen device, likely demonstrating how to grip the Adalimumab subcutaneous injection pen for administration.*

FDA Label Image

Figkk (Gp2017 Figl)

An instructional illustration showing a syringe positioned above a container labeled 'SHARPS' with a downward arrow indicating disposal of the syringe into the sharps container.*

FDA Label Image

Fige (Image 01)

An anatomical diagram showing recommended subcutaneous injection sites for Adalimumab injection, solution. Areas shaded include the lower abdomen and the front upper thighs on both legs, indicating where the injection can be administered subcutaneously.*

FDA Label Image

Figf (Image 02)

An instructional illustration showing a hand pinching the skin on a thigh with arrows indicating a circular motion, presumably demonstrating part of the subcutaneous injection technique for Adalimumab injection solution.*

FDA Label Image

Figl (Image 03)

An instructional illustration showing a hand holding a syringe above a sharps disposal container labeled 'SHARPS.' The image demonstrates the proper disposal method for injectable devices like syringes used with subcutaneous injection medications such as Adalimumab.*

FDA Label Image

Figa (Image 04)

An instructional diagram illustrating the parts of an Adalimumab injection pen device. Labeled components include the needle cap, needle guard, viewing window with label and expiration date, finger flange, needle guard wings, plunger, and plunger head. The diagram visually explains the device's subcutaneous injection components.*

FDA Label Image

Figc (Image 05)

An illustration of a subcutaneous injection device, shown as a syringe with a plunger, dose window, and finger grip. The image likely represents the administration method for Adalimumab injection solution in prefilled format, with no visible text or labeling on the device.*

FDA Label Image

Figd (Image 06)

An instructional illustration showing a subcutaneous injection device designed for Adalimumab solution. The image depicts the injection syringe with a needle guard and a plunger, used for delivering the medication subcutaneously.*

FDA Label Image

Figg (Image 07)

An instructional illustration showing a hand holding a syringe labeled Adalimumab, with the other hand removing the needle cap by pulling it straight off. The image demonstrates the step to prepare the Adalimumab subcutaneous injection prior to administration.*

FDA Label Image

Figh (Image 08)

An instructional illustration showing a person administering a subcutaneous injection using a syringe held by one hand, with the other hand stabilizing the injection site on the skin.*

FDA Label Image

Figi (Image 09)

An instructional diagram illustrating the proper technique for holding and using a subcutaneous injection pen. The image highlights finger placement on the injector device and shows a close-up of the needle exposure for subcutaneous injection, related to the use of Adalimumab injection solution.*

FDA Label Image

Figj (Image 10)

An instructional black-and-white line drawing showing a hand holding a prefilled syringe, demonstrating administration of a subcutaneous injection by pressing the plunger to release the solution through the needle into the skin.*

FDA Label Image

Figk (Image 11)

An instructional illustration showing a hand holding a small prefilled syringe, demonstrating the removal of a cap by pulling it straight off. The syringe contains a medication solution, identified as Adalimumab injection for subcutaneous use.*

FDA Label Image

Figaa (Image 13)

An instructional diagram showing parts of a subcutaneous injection pen or syringe labeled as Needle, Needle guard, Cap, Internal needle cover, and Viewing window. The diagram highlights the components related to the injection device.*

FDA Label Image

Figbb (Image 14)

An instructional illustration depicting four items in sequence separated by plus signs: a wipe labeled 'WIPE,' a cotton ball, a container labeled 'SHARPS,' and an adhesive bandage.*

FDA Label Image

Figcc (Image 15)

An instructional diagram of an Adalimumab injection pen showing a detailed view of the pen's components, including a labeled "Viewing window" and an "EXP" (expiration) date area on the pen's side. The pen is depicted with a protective cap at one end.*

FDA Label Image

Figure 10a (Image 27)

An instructional diagram of a subcutaneous injection device for Adalimumab. The labeled parts include the plunger rod, finger grip, and needle cap, illustrating components involved in administering the injection solution.*

FDA Label Image

Figure 10c (Image 28)

An anatomical illustration showing preferred subcutaneous injection sites on a human body. The highlighted areas include the abdomen around and below the navel and the outer front thighs.*

FDA Label Image

Figure 10d (Image 29)

An instructional illustration showing a hand preparing to inject a subcutaneous injection into the thigh. The image includes arrows indicating a circular motion on the skin surface, likely for cleansing or application technique prior to injection.*

FDA Label Image

Figure 10e (Image 30)

An instructional line drawing showing a hand removing a cap from a syringe containing medication, with the other hand holding the syringe, indicating preparation for injection.*

FDA Label Image

Figure 10f (Image 31)

An instructional illustration showing a hand administering a subcutaneous injection with a syringe held at a 45-degree angle into the skin of another hand's finger area. The image depicts the proper technique for injection angle and placement.*

FDA Label Image

Figure 10g (Image 32)

An instructional illustration showing a hand administering a subcutaneous injection with a syringe. Enlarged circular insets highlight specific syringe features involved in the injection process.*

FDA Label Image

Figure 10h (Image 33)

An instructional illustration showing a hand holding a syringe above a container labeled "SHARPS," demonstrating the proper disposal of the syringe into the sharps disposal container.*

FDA Label Image

40-04 Pen Label (Image 34)

Adalimumab 40 mg/0.4 mL injection label for subcutaneous use. The label includes usage instructions such as single-dose prefilled syringe/pen, sterile contents, and the need to dispense an enclosed medication guide. It is labeled by Sandoz Inc, a Novartis division, with instructions in blue and orange text on a white background.*

FDA Label Image

40-04 Pfs Label (Image 35)

Adalimumab 40 mg/0.4 mL subcutaneous injection label from Sandoz Inc. The label indicates single-dose prefilled syringes with 2 sterile safety needles and a need guard. Each carton contains 2 prefilled syringes. It specifies the product is for subcutaneous use only and requires the enclosed medication guide before use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.